<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03302182</url>
  </required_header>
  <id_info>
    <org_study_id>ZYYY-LTNW-BE-2017-05-2</org_study_id>
    <nct_id>NCT03302182</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects</brief_title>
  <acronym>RTV</acronym>
  <official_title>An Open-label, Randomized Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and bioequivalence of Ritonavir&#xD;
      tablet 100 mg versus NORVIR 100 mg tablet in healthy Chinese adult participants under fasting&#xD;
      or fed condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence&#xD;
      Study with a washout period of 6 days. During each session, the subjects will be administered&#xD;
      a single dose of 100mg Ritonavir (one Ritonavir Tablet 100mg or one NORVIR Tablet 100mg)&#xD;
      under fasting or fed condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2017</start_date>
  <completion_date type="Actual">December 4, 2017</completion_date>
  <primary_completion_date type="Actual">November 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>36 hours post-dose on Day 1,7</time_frame>
    <description>Maximum Observed Plasma Concentration for ritonavir&#xD;
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>36 hours post-dose on Day 1,7</time_frame>
    <description>Time to Reach the Maximum Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>Time Frame: 36 hours post-dose on Day 1,7</time_frame>
    <description>Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for ritonavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-36h)</measure>
    <time_frame>36 hours post-dose on Day 1,7</time_frame>
    <description>Area Under the Plasma Concentration-Time Curve From Time 0 to 36 hours Postdose for ritonavir</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>fasting group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.&#xD;
For group1:&#xD;
cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg&#xD;
For group2:&#xD;
cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.&#xD;
For group3:&#xD;
cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg&#xD;
For group4:&#xD;
cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir for cycle1 and NORVIR for cycle 2</intervention_name>
    <description>During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .</description>
    <arm_group_label>Fed group</arm_group_label>
    <arm_group_label>fasting group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NORVIR for cycle 1 and Ritonavir for cycle 2</intervention_name>
    <description>During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .</description>
    <arm_group_label>Fed group</arm_group_label>
    <arm_group_label>fasting group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers of 18-45 years old.&#xD;
&#xD;
          2. Male (weight ≥50kg);Female (weight ≥45kg)&#xD;
&#xD;
          3. Body mass index (BMI) between 19~28 kg/m2;&#xD;
&#xD;
          4. In good health as determined by a physician/investigator based on medical history,&#xD;
             vital signs, electrocardiogram (ECG), laboratory tests and physical examination&#xD;
             findings at screening;&#xD;
&#xD;
          5. Female participant with negative result of HCG test and agrees to use adequate&#xD;
             contraception from signing of informed consent form throughout the duration of the&#xD;
             study and for 6 months after the last dose of study drug;&#xD;
&#xD;
          6. Male participant agrees to use adequate contraception and have no plan to donate sperm&#xD;
             from signing of informed consent form throughout the duration of the study and for 6&#xD;
             months after the last dose of study drug;&#xD;
&#xD;
          7. Subject who totally understand the aim and progress of this clinical trial, make&#xD;
             decision by his/her free will, and signed a consent form to follow the progress;&#xD;
&#xD;
          8. In the opinion of the investigator, the participant is capable of understanding and&#xD;
             complying with protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who cannot tolerate venipuncture.&#xD;
&#xD;
          2. Allergy/hypersensitivity (including drug allergy) which is deemed relevant to the&#xD;
             trial as judged by the investigator;&#xD;
&#xD;
          3. Subject who has past or present history of any serious diseases, including (but not&#xD;
             limited to) digestive, cardiovascular, respiratory, urinary, musculoskeletal,&#xD;
             endocrine, psychiatric or neurological, hematologic, immunological or metabolic&#xD;
             disorders;&#xD;
&#xD;
          4. Abnormal results of physical examination (hematology, urine test,blood biochemistry&#xD;
             etc.), vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) or x-ray&#xD;
             with clinical significance.&#xD;
&#xD;
          5. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)&#xD;
             antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test;&#xD;
&#xD;
          6. Women who is during lactation, pregnancy or plan to have baby recently.&#xD;
&#xD;
          7. Women with positive result of HCG test.&#xD;
&#xD;
          8. Subject who refuse to use adequate contraception from signing of informed consent form&#xD;
             throughout the duration of the study and for 6 months after the last dose of study&#xD;
             drug;&#xD;
&#xD;
          9. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol&#xD;
             abuse (defined as alcohol consumption exceeding 14 units per week) within 6 months&#xD;
             preceding this study or is unwilling to agree to abstain from alcohol and drugs&#xD;
             throughout the study;&#xD;
&#xD;
         10. Heavy smokers (&gt;5 cigarettes per day) within 6 months preceding this study or is&#xD;
             unwilling to agree to abstain from smoking throughout the study;&#xD;
&#xD;
         11. Positive test results for alcohol or drug at Screening;&#xD;
&#xD;
         12. History of hospitalization or surgery within 3 months preceding this study.&#xD;
&#xD;
         13. Blood donation within the last 2 months (&gt;= 400 ml), or have a plan to donate blood&#xD;
             within 1 month after this study;&#xD;
&#xD;
         14. Intake of any other drug which might influence the results of the trial during two&#xD;
             weeks previous to the start of the study.&#xD;
&#xD;
         15. Participation in another study with an investigational drug within the last 3 months&#xD;
             preceding this study;&#xD;
&#xD;
         16. History of gastrointestinal surgery, vagotomy, enterotomy or other surgery that may&#xD;
             influence gastrointestinal motility,PH or gastrointestinal absorption.&#xD;
&#xD;
         17. Intake of grapefruit or orange (or other food containing grapefruit or orange) 3 days&#xD;
             previous to the start of the study. Intake of tea,coffee or other drink containing&#xD;
             coffee more than 1L per day.&#xD;
&#xD;
         18. Consideration by the investigator, for any reason, that the subject is an unsuitable&#xD;
             candidate to receive Ritonavir.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 30, 2017</study_first_submitted>
  <study_first_submitted_qc>September 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

